KemPharm to Present at Multiple Upcoming Investor Conferences
May 11, 2022 07:30 ET
|
KemPharm
CELEBRATION, Fla., May 11, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company focused on the discovery and development of novel...
KemPharm Announces Submission of Investigational New Drug Application for Phase 2 Trial of KP1077 in Idiopathic Hypersomnia (IH)
May 05, 2022 07:30 ET
|
KemPharm
Upon IND clearance, KemPharm anticipates initiating KP1077 Phase 2 IH trial as early as the second half of 2022 CELEBRATION, Fla., May 05, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH)...
KemPharm to Report First Quarter 2022 Financial Results
May 04, 2022 16:30 ET
|
KemPharm
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Thursday, May 12, 2022, 5:00 p.m. ET CELEBRATION, Fla., May 04, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS:...
KemPharm Doses First Subject in Phase 1 Clinical Trial Evaluating Cardiovascular Safety of Serdexmethylphenidate (SDX)
April 19, 2022 07:30 ET
|
KemPharm
Cardiovascular safety is a key component of the KP1077 product profile; Topline data comparing SDX to other stimulant treatments expected in Q3 2022 CELEBRATION, Fla., April 19, 2022 (GLOBE...
KemPharm Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Corporate Updates
March 30, 2022 16:05 ET
|
KemPharm
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today, March 30, 2022, 5:00 p.m. ET Corporate and Regulatory Highlights Announced strategic focus on developing...
KemPharm to Participate in Maxim’s 2022 Virtual Growth Conference
March 24, 2022 08:00 ET
|
KemPharm
CELEBRATION, Fla., March 24, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today...
KemPharm Announces Full Data Set from Higher-Dose Serdexmethylphenidate (SDX) Phase 1 Clinical Trial
March 21, 2022 07:30 ET
|
KemPharm
Data demonstrate higher doses of SDX were generally well-tolerated and produced targeted pharmacodynamic effects that may be beneficial for the treatment of idiopathic hypersomnia (IH) and other sleep...
KemPharm Earns $1.975 Million Fee from Corium Following FDA Approval of the Corium Product ADLARITY® (donepezil transdermal system)
March 16, 2022 07:30 ET
|
KemPharm
KemPharm team provided development and regulatory services to Corium pursuant to a master development services agreement CELEBRATION, Fla., March 16, 2022 (GLOBE NEWSWIRE) -- KemPharm,...
KemPharm to Report Fourth Quarter and Full-Year 2021 Results
March 10, 2022 07:30 ET
|
KemPharm
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Wednesday, March 30, 2022, 5:00 p.m. ET CELEBRATION, Fla., March 10, 2022 (GLOBE NEWSWIRE) -- KemPharm,...
KemPharm Completes KP1077 Pre-IND Meeting Process with FDA
February 23, 2022 07:30 ET
|
KemPharm
KemPharm Positioned to Submit IND Application for KP1077 for Idiopathic Hypersomnia by Mid-2022 CELEBRATION, Fla., Feb. 23, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH), a specialty...